These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36075849)

  • 1. FSH receptor genotype and its influence on the results of donor ovarian stimulation using corifollitropin alfa.
    Lledó B; Ortiz JA; Hortal M; Cascales A; Morales R; Guerrero J; Bernabeu A; Bernabeu R
    Reprod Biomed Online; 2022 Nov; 45(5):943-946. PubMed ID: 36075849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corifollitropin alfa compared with follitropin beta in poor responders undergoing ICSI: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Bosdou JK; Zepiridis L; Chatzimeletiou K; Makedos A; Masouridou S; Triantafillidis S; Mitsoli A; Tarlatzis BC
    Hum Reprod; 2015 Feb; 30(2):432-40. PubMed ID: 25492411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of recombinant versus highly purified follicle-stimulating hormone according to follicle-stimulating hormone receptor genotype.
    Lledó B; Dapena P; Ortiz JA; Morales R; Llacer J; Bernabeu R
    Pharmacogenet Genomics; 2016 Jun; 26(6):288-93. PubMed ID: 26959715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for oocyte donors].
    Benchabane M; Santulli P; Maignien C; Bourdon M; De Ziegler D; Chapron C; Gayet V
    Gynecol Obstet Fertil Senol; 2017 Feb; 45(2):83-88. PubMed ID: 28368800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large, comparative, randomized double-blind trial confirming noninferiority of pregnancy rates for corifollitropin alfa compared with recombinant follicle-stimulating hormone in a gonadotropin-releasing hormone antagonist controlled ovarian stimulation protocol in older patients undergoing in vitro fertilization.
    Boostanfar R; Shapiro B; Levy M; Rosenwaks Z; Witjes H; Stegmann BJ; Elbers J; Gordon K; Mannaerts B;
    Fertil Steril; 2015 Jul; 104(1):94-103.e1. PubMed ID: 26003273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol.
    Fatemi HM; Doody K; Griesinger G; Witjes H; Mannaerts B
    Hum Reprod; 2013 Feb; 28(2):442-52. PubMed ID: 23136144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study.
    Tsakiridis I; Najdecki R; Tatsi P; Timotheou E; Kalinderi K; Michos G; Virgiliou A; Yarali H; Athanasiadis A; Papanikolaou EG
    JBRA Assist Reprod; 2020 Oct; 24(4):436-441. PubMed ID: 32489086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of follicle-stimulating hormone receptor N680S polymorphism on the efficacy of follicle-stimulating hormone stimulation on donor ovarian response.
    Lledo B; Guerrero J; Turienzo A; Ortiz JA; Morales R; Ten J; Llacer J; Bernabeu R
    Pharmacogenet Genomics; 2013 May; 23(5):262-8. PubMed ID: 23470615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction.
    Souza PMG; Carvalho BR; Nakagawa HM; Rassi TRE; Barbosa ACP; Silva AA
    JBRA Assist Reprod; 2017 Jun; 21(2):67-69. PubMed ID: 28609269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for in vitro fertilization: a meta-analysis.
    Fensore S; Di Marzio M; Tiboni GM
    J Ovarian Res; 2015 Jun; 8():33. PubMed ID: 26036214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction.
    Croxtall JD; McKeage K
    BioDrugs; 2011 Aug; 25(4):243-54. PubMed ID: 21815699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF.
    Fauser BC; Alper MM; Ledger W; Schoolcraft WB; Zandvliet A; Mannaerts BM;
    Reprod Biomed Online; 2010 Nov; 21(5):593-601. PubMed ID: 20843746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis.
    Griesinger G; Boostanfar R; Gordon K; Gates D; McCrary Sisk C; Stegmann BJ
    Reprod Biomed Online; 2016 Jul; 33(1):56-60. PubMed ID: 27178762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Ala307Thr polymorphism of the follicle-stimulating hormone receptor (FSHR) gene is associated with the dose of recombinant FSH received during IVF/ICSI treatment.
    Dieamant F; Petersen CG; Vagnini LD; Petersen B; Ricci J; Nicoletti A; Zamara C; Oliani AH; Oliveira JBA; Franco JG
    JBRA Assist Reprod; 2023 Mar; 27(1):78-84. PubMed ID: 36995260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the follicular output rate after controlled ovarian stimulation with daily recombinant follicle-stimulating hormone versus corifollitropin alfa.
    Griesinger G; Teal V; McCrary Sisk C; Ruman J
    Eur J Obstet Gynecol Reprod Biol; 2019 Jan; 232():101-105. PubMed ID: 30529793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.
    Devroey P; Boostanfar R; Koper NP; Mannaerts BM; Ijzerman-Boon PC; Fauser BC;
    Hum Reprod; 2009 Dec; 24(12):3063-72. PubMed ID: 19684043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ser680Asn polymorphism in the follicle-stimulating hormone receptor gene is associated with the ovarian response in controlled ovarian hyperstimulation.
    Huang X; Li L; Hong L; Zhou W; Shi H; Zhang H; Zhang Z; Sun X; Du J
    Clin Endocrinol (Oxf); 2015 Apr; 82(4):577-83. PubMed ID: 25132286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: an updated meta-analysis of 16 cohort studies.
    Tang H; Yan Y; Wang T; Zhang T; Shi W; Fan R; Yao Y; Zhai S
    J Assist Reprod Genet; 2015 Dec; 32(12):1801-10. PubMed ID: 26481502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized dose-response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation.
    Corifollitropin Alfa Dose-finding Study Group
    Hum Reprod; 2008 Nov; 23(11):2484-92. PubMed ID: 18684735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.